Edward Fruitman
Psychiatry · Hewlett, NYNPI 1558434134
Payments from drug & device makers
Across 1,292 payments — averaging $333.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$159K
- Neurocrine Biosciences, Inc.$113K
- Teva Pharmaceuticals USA, Inc.$83K
- Alkermes, Inc.$35K
- E.r. Squibb & Sons, L.L.C.$30K
- Idorsia Pharmaceuticals US Inc$5K
- plus $7K from 30 others
What the payments were for
- Consulting fees$18,6254%
- Speaking & faculty fees$373,92087%
- Travel & lodging$9,3412%
- Food & beverage$28,7947%
- Education$2900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$108,820
- LYBALVI$107,395
- UZEDY$75,712
- VRAYLAR$55,149
- ARISTADA$28,820
- COBENFY$25,837
- ARISTADA INITIO$7,205
- QUVIVIQ$4,785
- AUSTEDO$3,321
- M22$1,366
- BOTOX$250
- Austedo XR$107
- TRINTELLIX$103
How this compares
$430,970 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 86 | $671,713 |
| Invega TrinzaPaliperidone Palmitate | 17 | $181,350 |
| AristadaAripiprazole Lauroxil | 43 | $143,553 |
| VraylarCariprazine Hcl | 80 | $123,818 |
| UzedyRisperidone | 42 | $120,883 |
| Abilify MaintenaAripiprazole | 37 | $100,655 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $45,134 |
| Invega SustennaPaliperidone Palmitate | 17 | $45,027 |
| MounjaroTirzepatide | 19 | $23,470 |
| Lurasidone Hcl | 47 | $23,454 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $21,033 |
| VyvanseLisdexamfetamine Dimesylate | 53 | $20,325 |
| TrintellixVortioxetine Hydrobromide | 27 | $12,755 |
| OzempicSemaglutide | 12 | $11,689 |
| Clozapine | 112 | $9,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $112,686 | $671,71386 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $317 | $226,37734 claims |
| Alkermes, Inc.Aristada, Lybalvi | $35,189 | $188,68771 claims |
| AbbVieVraylar | $158,690 | $123,81880 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $82,969 | $120,88342 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $135 | $33,08080 claims |
| Axsome Therapeutics, Inc.Auvelity | $622 | $21,03313 claims |
| Novo NordiskOzempic | $80 | $11,68912 claims |
| MerckBelsomra | $196 | $5,31512 claims |
| Corium, LLCAzstarys | $247 | $4,34011 claims |
| Almatica Pharma LLCSertraline Hcl | $46 | $860130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Hewlett
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.